Clinical Trial

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-10-13; most recent amendment 2024-11-21.
Trial Details
NCT Number NCT05093374
Lead Sponsor Medical University of Vienna
Conditions Exudative Macular Degeneration
Enrollment 290 participants
Start Date 2021-03-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-25